Status:
ACTIVE_NOT_RECRUITING
The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer
Lead Sponsor:
University Hospital Birmingham NHS Foundation Trust
Conditions:
Pancreatic Adenocarcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
There is a high rate of R1 resection following patients undergoing pancreaticoduodenectomy for pancreatic cancer. The most commonly positive margin is the SMA. Peri-adventitial dissection has been pro...
Detailed Description
Pancreatic cancer is the 4th cause of cancer death in Europe. With the existing treatments the overall 5-year survival remains 8%. For patients with non-metastatic disease, many are conventionally jud...
Eligibility Criteria
Inclusion
- All adult (≥ 18 years old) patients with a non-metastatic (based on NCCN definition) on imaging pancreatic tumour of the head or uncinate process treated with a pancreaticoduodenectomy
Exclusion
- All paediatric patients (\< 18 years old)
- Patients that cannot provide consent
- All borderline, locally advanced and metastatic pancreatic tumours on imaging (based on NCCN criteria)
- All patients with a cytological or histological diagnosis of cholangiocarcinoma, ampullary and duodenal carcinoma
- All patients with benign disease or dysplasia with no evidence of malignancy
Key Trial Info
Start Date :
April 6 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 6 2026
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT04902352
Start Date
April 6 2021
End Date
October 6 2026
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Birmingham NHS Foundation Trust
Birmingham, County (Optional), United Kingdom, B15 2GW